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Glycopeptide resistance has been studied in detail in enterococci and staphylococci. In these microorganisms,
high-level resistance is achieved by replacing the C-terminal D-alanyl-D-alanine of the nascent peptidoglycan with
D-alanyl–D-lactate or D-alanyl–D-serine, thus reducing the affinities of glycopeptides for cell wall targets. Reorgani-
zation of the cell wall is directed by the expression of the van gene clusters. The identification of van gene homologs
in the genomes of several glycopeptide-producing actinomycetes suggests the involvement of a similar self-resistance
mechanism to avoid suicide. This report describes a comprehensive study of self-resistance in Actinoplanes teicho-
myceticus ATCC 31121, the producer of the clinically relevant glycopeptide teicoplanin. A. teichomyceticus ATCC
31121 showed a MIC of teicoplanin of 25 mg/ml and a MIC of vancomycin of 90 mg/ml during vegetative growth. The
vanH, vanA, and vanX genes of A. teichomyceticus were found to be organized in an operon whose transcription was
constitutive. Analysis of the UDP-linked peptidoglycan precursors revealed the presence of UDP-glycomuramyl
pentadepsipeptide terminating in D-alanyl–D-lactate. No trace of precursors ending in D-alanyl–D-alanine was
detected. Thus, the van gene complex was transcribed and expressed in the genetic background of A. teichomyceticus
and conferred resistance to vancomycin and teicoplanin through the modification of cell wall biosynthesis. During
teicoplanin production (maximum productivity, 70 to 80 mg/ml), the MIC of teicoplanin remained in the range of
25 to 35 mg/ml. Teicoplanin-producing cells were found to be tolerant to high concentrations of exogenously added
glycopeptides, which were not bactericidal even at 5,000 mg/ml.
Glycopeptide antibiotics are produced by actinomycetes and
inhibit the synthesis of bacterial cell wall by blocking pepti-
doglycan assembly. They bind to the D-alanyl–D-alanine (D-
Ala–D-Ala) C terminus of the nascent peptidoglycan and pre-
vent it from being utilized in the following cross-linking
reactions catalyzed by transglycosylases and transpeptidases
(18, 38, 44). The structurally related glycopeptides vancomycin
and teicoplanin have been used in clinical settings since 1958
and 1988, respectively. These drugs are still extensively used
against multiresistant enterococci and methicillin-resistant
staphylococci. Concern about vancomycin-resistant enterococci
has been increasing during the last decade, and highly vanco-
mycin resistant Staphylococcus aureus isolates have recently
appeared in clinical specimens (10, 11).
Two resistance phenotypes, VanA and VanB, have been
extensively studied in enterococci and are considered of main
importance, since the genes responsible for resistance (van
genes) are inducible and transferable and confer high-level
resistance to vancomycin (at concentrations up to 1,000 mg/ml
or more) (42). The vanA gene cluster also confers high-level
resistance to teicoplanin (4, 9, 15, 16). Other resistant pheno-
types among enterococci (VanC, VanD, VanE, and VanG)
showing a lower level of resistance to vancomycin and none or
poor resistance to teicoplanin have been described (reviewed
in reference 42). In VanA, VanB, and VanD enterococci, van
genes direct the synthesis of peptidoglycan precursors termi-
nating in the depsipeptide D-alanyl-D-lactate (D-Ala–D-Lac),
whereas in VanC, VanE, and VanG strains, the C-terminal end
is D-alanyl–D-serine (D-Ala–D-Ser) in place of the usual D-Ala-
D-Ala. The modification of the target drastically reduces affin-
ity for the glycopeptide, thus producing resistance (38). The
key enzymes in VanA and VanB enterococci are a dehydro-
genase (VanH encoded by the vanH/vanHB gene) that converts
pyruvate into D-lactate (9, 16), a ligase (VanA or VanB en-
coded by the respective van gene) that joins D-alanine and
D-lactic acid (9, 16, 34), and a D,D-dipeptidase (VanX encoded
by the vanX/vanXB gene) that cleaves the D-Ala–D-Ala pro-
duced by the normal peptidoglycan synthesis pathway (16, 45,
51). The genes vanH, vanA/vanB, and vanX are organized in a
cluster and are often associated with other genes encoding
additional but not essential functions (1, 3, 15, 17, 50). A
two-component regulatory system, composed of a membrane-
associated sensor kinase (VanS or VanSB) and a cytoplasmic
response regulator that acts as a transcriptional activator (VanR
or VanRB), regulates the expression of vanH, vanA/vanB, and
vanX (5).
An intriguing hypothesis is that bacterial pathogens have
actually acquired antibiotic resistance mechanisms from anti-
biotic producers, although there is no conclusive evidence
which proves gene transfer (19, 39, 40). In fact, van-like genes
with a high level of homology and an organization similar to
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those of the pathogenic enterococci have been identified in
glycopeptide-producing actinomycetes (28, 30–33), in which
they might play a role in avoiding self-inhibition during anti-
biotic production. van-like genes are present in glycopeptide
producers, such as Amycolatopsis spp., which are producers of
vancomycin, chloroeremomycin, ristocetin, and avoparcin (30);
in Streptomyces toyocaensis NRRL15009, which is the producer
of A47934 (43); and in the teicoplanin producer Actinoplanes
teichomyceticus ATCC 31121 (48); but an understanding of
their active role in determining resistance is only at the begin-
ning. van-like genes are physically linked to the gene clusters
for the biosynthesis of A47934 (43) and teicoplanin (tcp clus-
ter) (48, 49), but this does not seem to be the case in the other
glycopeptide producers so far characterized (14). When the
vanA gene of Streptomyces toyocaensis (vanAst; vanA homolog)
was disrupted, the mutant showed reduced resistance to
A47934 but continued to produce this compound with a delay
of ca. 16 h in comparison with that for the parental strain (43).
One end of the tcp cluster contains seven genes likely involved
in teicoplanin resistance: murF2; the vanH, vanA, and vanX
genes of A. teichomyceticus (vanHat, vanAat, and vanXat, re-
spectively); the sensory kinase and the response regulator of a
putative two-component signal transduction system (ortholo-
gous to the vanS and vanR genes of enterococci); and a short-
chain dehydrogenase of unknown function (29, 49). These
seven genes of A. teichomyceticus were cloned in Streptomyces
coelicolor, but their effect on the teicoplanin resistance of the
recipient strain was marginal (47, 48). On the other hand, van-like
genes conferring resistance to vancomycin but not to teicoplanin
were found in S. coelicolor itself, even though this strain lacks the
genetic potential to produce glycopeptides (8, 20).
The purpose of this paper is to clarify the role of van genes
in the resistance mechanisms used by the teicoplanin producer
A. teichomyceticus during the phases of vegetative growth and
the production of teicoplanin. Besides the genetic evidence for
the presence of van-like genes, no insight into the resistance
phenotype of A. teichomyceticus has so far been reported. The
complex life cycle, the need for properly tailored microbiolog-
ical methods in handling this rare actinomycete, and the lack of
suitable genetic manipulation tools have probably hampered,
until now, a comprehensive understanding of resistance com-
parable to that achieved for pathogenic enterococci.
MATERIALS AND METHODS
Strains and growth conditions. The mycelium of the teicoplanin producer
strain A. teichomyceticus ATCC 31121 was maintained as a lyophilized master
cell bank. Mycelium from the master cell bank was streaked onto slants of salt
medium (SM; glucose [Sigma-Aldrich, St. Louis, MO], 10 g/liter; Bacto
peptone [Difco, Detroit, MI], 4 g/liter; Bacto yeast extract [Difco], 4 g/liter;
MgSO4 z 7H2O [Sigma-Aldrich], 0.5 g/liter; KH2PO4 [Sigma-Aldrich], 2 g/liter;
K2HPO4 [Sigma-Aldrich], 4 g/liter; deionized water up to 1 liter) solidified with
agar (15 g/liter; Sigma-Aldrich). After growth, the mycelium from a slant was
homogenized in 10 ml of isotonic saline and inoculated in SM, grown for 96 h at
28°C with aeration, and stored as working cell bank (WCB) in 1.5-ml cryovials at
280°C for further experiments. The WCB was used to inoculate all the cultures
for the experiments described here. Unless otherwise specified, the cultures were
grown in medium (SM or SM agar) in which the production of teicoplanin did
not occur, as demonstrated by high-pressure liquid chromatography (HPLC)
analysis of the culture extracts, as reported below. These cultures/media are
defined here as vegetative to distinguish them from productive cultures/media
which did support teicoplanin production.
For DNA/RNA extraction, 2 ml WCB was inoculated into 100 ml of SM in a
500-ml baffled flask to which 5 ml sterile glass beads was added, and the flask was
incubated at 28°C for 72 h on a rotary shaker at 200 rpm. Mycelium from this
seed culture was transferred into 100 ml fresh SM to give an inoculum density of
10 g/liter (wet weight), and growth was allowed for 24 h at 28°C and 200 rpm.
Vancomycin (Sigma-Aldrich) or teicoplanin (Sanofi-Aventis, Paris, France) was
added, when required, at subinhibitory concentrations of 30 mg/ml and 4 mg/ml,
respectively.
DNA/RNA extraction. Genomic DNA of A. teichomyceticus ATCC 31121 was
extracted by a previously described method (24) from an SM vegetative culture
grown to the exponential phase (24 to 48 h). RNA was extracted from mycelium
induced for 1, 2, 4, 8, and 24 h with vancomycin or teicoplanin. Control samples
to which glycopeptide was not added were extracted at the same time intervals.
Mycelium was incubated in 2 ml of Tris-EDTA buffer containing 10 mg/ml
lysozyme (Sigma-Aldrich) for 10 min; then, RNA isolation was carried out by
following the protocol for the TRIzol reagent (Invitrogen, Carlsbad, CA). For
further purification, an RNeasy Midi kit (QIAGEN, Hilden, Germany) was used
according to the supplier’s instructions. Residual DNA from RNA samples was
removed by incubation with 10 U RNase-free DNase I (Roche, Basel, Switzer-
land) at 37°C for 1 h. The DNase I was then extracted with phenol and chloro-
form-isoamyl alcohol (24:1; Sigma-Aldrich). Finally, the RNA was recovered by
ethanol-sodium acetate precipitation and centrifugation and was stored at 280°C
in diethyl pyrocarbonate (Sigma-Aldrich)-treated water at a final concentration
of 1 mg/ml.
Genetic analyses. DNA manipulations were performed by standard methods
(46) unless otherwise specified. The positions reported for PCR and cDNA
synthesis primers refer to the sequence in the GenBank database with accession
no. AJ605139. Total RNA samples from the different cultivation conditions were
accurately quantified with a UV 2100 spectrophotometer (Shimadzu, Kyoto,
Japan) and normalized by direct comparison on 1% agarose electrophoresis gels
(Sigma-Aldrich). Five micrograms of each RNA sample was reverse transcribed
by using the SuperScript first-strand synthesis system for reverse transcription-
PCR (RT-PCR; Invitrogen). The first-strand synthesis reaction was primed with
random hexamers for 1 h at 37°C. Different cDNA concentrations were then
used as the template for amplification of vanXat with primers vanXFw (posi-
tion 14301-59-TTCGCGTTCGTGGACGAG-39-position 14319) and vanXRev (po-
sition 14897-59-CTACACGATCGGAAAATCAAA-39-position 14876); vanAat was
amplified with primers vanAFw (position 13269-59-CGGCATCATCTTCGGCG-
39-position 13286) and vanARev (position 14273-59-AGGGCCAGCGACACGA
T-39-position 14256); and vanHat was amplified with primers vanHFw (position
12057-59-AGCGCGGACGCCATCCGT-39-position 12075) and vanHRev (posi-
tion 13256-59-CCCATGCTGTTGTTCCCT-39-position 13238). Chromosomal DNA of
A. teichomyceticus ATCC 31121 was used as a positive control, and total RNA
without first-strand synthesis was used to test for genomic DNA contamination.
The amplification products were separated on a 1% agarose gel. Semiquantita-
tive PCR of the vanXat gene was performed as reported previously (36). In brief,
1:2 serial dilutions of the RNA reverse transcription product were amplified as
described above with primers vanXFw and vanXRev by using 25 instead of 30
amplification cycles in order to compare the products during the exponential
phase of the PCR and to quantify the relative mRNA levels. Samples were
separated on a 1% agarose gel, and the relative transcript amount was deter-
mined by densitometric quantification with MI Image Analysis software (Kodak,
Rochester, NY). In order to ensure that the amount of total cDNA was the same
in the different samples, the same set of cDNA dilutions used as the template for
the vanXat gene was also used to amplify the 16S rRNA genes.
Reverse transcription of the putative van operon encompassing the vanHat,
vanAat, and vanXat genes was carried out by using 5 mg of total RNA as the
template and the gene-specific primer vanXRev. Different cDNA concentrations
were used as the template for PCR amplification with primers TevanHFw (po-
sition 12886-59-CACTTCACACCCCGCTCA-39-position 12904), which maps
844 bp downstream from the VanHat putative start, and TevanXRev (position
14639-59-GCTGTGACCGGACTTGGT-39-position 14620), which is located 351
bp downstream from the VanXat putative start. The conditions for amplification
were as described above. Chromosomal DNA of A. teichomyceticus ATCC 31121
was used as the positive control, and total RNA without first-strand synthesis was
used to test for genomic DNA contamination. The amplification product was
analyzed on a 1% agarose gel.
Sequence homology analysis was performed with the BLAST program, and
protein multisequence alignment was performed with the Clustal X program.
Antimicrobial activity assays. The MICs of teicoplanin and vancomycin were
determined by the broth microdilution methodology, according to the proce-
dures of the CLSI (formerly the NCCLS) (37), which were adapted to the
cultivation conditions and the duplication times of A. teichomyceticus ATCC
31121. Vegetative mycelium grown to the exponential phase (24 to 48 h) in SM
was harvested by centrifugation; suspended in isotonic saline; and fragmented by
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sonication with a VCX 400 sonicator (Sonics and Materials Inc., Newtown, CT)
at an intensity of 6 kHz and with the pulse on for 5 s and the pulse off for 3 s for
a total interval sufficient to give single unbranched hyphae with sizes ranging
from 1 to 5 mm (the sizes were checked with a microscope). The resulting cell
suspension was filtered through a 5-mm-pore-size Durapore membrane filter
(Millipore, Bedford MA), harvested by centrifugation, suspended in fresh SM at
a concentration of 10 g/liter (fresh weight), and dispensed in a set of flasks
containing vancomycin or teicoplanin at different concentrations. Growth was
allowed for 96 h at 28°C with shaking. The MIC was the first antibiotic concen-
tration that afforded no visible growth after 96 h of incubation.
Induction of glycopeptide resistance was investigated as follows. Mycelium was
grown in SM medium for 24 h at 28°C. Then, subinhibitory concentrations of
vancomycin (30 mg/ml) or teicoplanin (4 mg/ml) were added to the culture and
growth was allowed for a further 24 h. Finally, the vegetative mycelium was
sonicated and dispensed in flasks for MIC determination, as described above.
For the determination of the minimal bactericidal concentration, the sonicated
vegetative mycelium was inoculated in a set of flasks containing increasing
antibiotic concentrations and the flask was incubated at 28°C with shaking for a
time interval equal to three generations (approximately 24 h), which was esti-
mated in SM without any antibiotic. Mycelium from each flask was then washed
with isotonic saline, diluted, and plated on SM agar plates without added anti-
biotic. After 15 days at 28°C, the fraction of cells which survived in the presence
of the respective antibiotic concentrations in the flask and which were thus able
to grow on a plate was determined. Antibiotic concentrations that resulted in a
percentage of survivors less than 0.1 were considered bactericidal (27).
Teicoplanin production. Two milliliters of A. teichomyceticus WCB was inoc-
ulated in SM and grown for 72 h at 28°C on a rotary shaker at 200 rpm. Ten
milliliters of this vegetative culture was then transferred to 100 ml of production
medium C (glucose [Sigma-Aldrich], 20 g/liter; Bacto yeast extract [Difco], 5
g/liter; MgSO4 z 7H2O [Sigma-Aldrich], 1.5 g/liter; CaCO3 [Sigma-Aldrich], 0.5
g/liter; asparagine [Sigma-Aldrich]; 1.5 g/liter; NaCl [Sigma-Aldrich], 0.1 g/liter;
CaCl2 z 2H2O [Sigma-Aldrich], 0.1 g/liter; deionized water up to 1 liter). At
different times of incubation at 28°C and 200 rpm, total teicoplanin was extracted
by mixing 1 volume of whole culture and 3 volumes of borate buffer (100 mM
H3BO3 [Sigma-Aldrich], 100 mM NaOH [Sigma-Aldrich], pH 12). The samples
were then centrifuged (16,000 3 g for 15 min) and the glycopeptide-containing
supernatant was filtered through a Durapore membrane filter (pore size, 0.45
mm; Millipore). The teicoplanin bound to the mycelium was extracted as follows.
The culture samples were centrifuged (16,000 3 g for 15 min) in graduated vials
and decanted, and 1 volume of packed mycelium was suspended in 3 volumes of
borate buffer. The supernatant was then filtered as described above. Glycopep-
tide production was estimated by HPLC, which was performed on a 5-mm-
particle-size Ultrasphere ODS (Beckman Coulter Inc., Fullerton, CA) column
(4.6 by 250 mm) with elution at a flow rate of 1 ml/min with a 26-min linear
gradient from 25% to 37% phase B. Phase A was 20 mM HCOONH4 (pH 4.5;
Sigma-Aldrich) and CH3CN (Sigma-Aldrich) (95:5 [vol/vol]), and phase B was 20
mM HCOONH4 (pH 4.5) and CH3CN (5:95 [vol/vol]). Chromatography was
performed with a model 1100 HPLC system (Hewlett-Packard, Palo Alto, CA),
and UV detection was at 254 nm. Pure samples of teicoplanin (Sanofi-Aventis)
were used as the internal standard. For growth estimation, mycelium was col-
lected by centrifugation (3,250 3 g for 20 min) and was washed with 2 ml isotonic
saline. The dry weight was measured after 24 h of incubation in an 80°C oven.
For MIC determination during teicoplanin production, 10 g/liter of mycelium
was transferred from fermentative medium C to vegetative SM in the presence
of increasing teicoplanin concentrations. The effective antibiotic concentration in
the MIC flasks was the sum of the teicoplanin concentration added and the
concentration of teicoplanin produced and carried over into the mycelium. Fer-
mentations, growth estimations, and MIC determinations were performed in
triplicate.
Peptidoglycan precursor extraction and analysis. A. teichomyceticus ATCC
31121 peptidoglycan precursors were extracted by a method previously described
for Bacillus cereus (25), with some modification. Briefly, mycelium grown in
vegetative medium to the exponential phase (24 to 48 h) was incubated for 1 h
with 150 mg/ml ramoplanin (ca. eightfold the ramoplanin MIC; Biosearch Italia
SpA, Gerenzano, Italy) to block final assembly of the cell wall and thus to amplify
the cytoplasmic pool of uridine diphospho-linked precursors (6). Then, the cells
were harvested, suspended in water (0.1 g [fresh weight] per ml), and boiled for
20 min. After the mycelium was first cooled at room temperature and then in ice,
it was centrifuged at 39,000 3 g. The supernatant was lyophilized and dissolved
in 0.1 volume of water adjusted to pH 3 with formic acid. The samples were
analyzed by reversed-phase HPLC and electrospray ionization (ESI)-mass spec-
trometry (MS) on a LCQ-Deca spectrometer equipped with an ion-trap analyzer
(Thermo Finnigan, San Jose, CA). The samples were separated on a C18 column
(5 mm; 4.6 by 250 mm; Phenomenex Luna, Torrance, CA) eluted at a flow rate
of 1 ml/min with 2 min with 100% phase A and then a 50-min linear gradient to
100% phase B. Phase A was 2% CH3CN, 97.9% H2O, 0.1% HCOOH (vol/vol/
vol); and phase B was 95% CH3CN, 4.915% H2O, and 0.085% HCOOH (vol/
vol/vol). The column temperature was 22°C. The chromatographic UV absorp-
tion profile was provided with a photo diode array detector (UV6000; Thermo
Finnigan). One-fifth of the detector elution flow was split into the mass spec-
trometer. The MS spectra were obtained by electrospray ionization both in the
positive mode and in the negative mode under the following conditions. Sample
inlet conditions were as follows: capillary temperature, 250°C; sheath gas (N2), 80
LCQ arbitrary units; and auxiliary gas (N2), 20 LCQ arbitrary units. Sample inlet
voltage settings were as follows: positive polarity, 4.5 kV; negative polarity, 2.8
kV; capillary voltage, 4 V; and tube lens offset, 30 V. Helium was used as the
buffer and collision gas. MS-MS analyses were performed at a collision energy of
30 keV. All the spectra were acquired in the 150- to 2,000-atomic-mass-unit mass
range.
RESULTS AND DISCUSSION
Organization and transcription of van genes in A. teichomy-
ceticus. In A. teichomyceticus ATCC 31121, van gene homologs
were found in a region contiguous with the tcp cluster (47–49).
In the present study we have analyzed by RT-PCR the expres-
sion of van genes during growth in vegetative medium. Under
these conditions, A. teichomyceticus did not produce detectable
quantities of teicoplanin (HPLC detection limit, 0.1 mg/liter)
which could eventually induce the van genes and, conse-
quently, interfere with the investigation of gene expression.
First, qualitative monitoring of transcription indicated that the
vanAat and vanXat genes are always transcribed, independently
of whether exogenous vancomycin or teicoplanin is added or
not added as an inducer (data not shown). Amplification of the
cDNA obtained with primers TevanHFw and TevanXRev
(mapping 373 bp upstream from the stop codon of vanH and
350 bp downstream from the start codon of vanX, respectively)
indicated that the vanHat, vanAat, and vanXat genes are co-
transcribed in an unique polycistronic mRNA (data not
shown). Next, the van transcript levels of cultures grown either
for 8 h or for 24 h in the presence of exogenously added
vancomycin (30 mg/ml) or teicoplanin (4 mg/ml) were com-
pared to those of cultures grown in the absence of the glyco-
peptides by semiquantitative RT-PCR with primers vanXFw
and vanXRev. The subinhibitory glycopeptide concentrations
used (previously defined in MIC experiments; see below) did
not influence the growth rate of A. teichomyceticus. Densito-
metric analysis of the RT-PCR products obtained from the
vancomycin- and teicoplanin-induced cultures showed that for
each dilution of the cDNA template, the amounts of the am-
plification products corresponding to the vanXat transcript
were essentially comparable to those achieved in uninduced
cultures (data not shown). Vancomycin-induced cultures
showed only a slightly (twofold) greater amount of transcript at
8 h, but this difference was no longer apparent after 24 h of
induction. These results suggest the constitutive transcription
of the A. teichomyceticus van cluster.
Mutations in A. teichomyceticus VanS suggest impaired ac-
tivity of the sensor kinase. Constitutive expression of the van
genes determined by mutation of the VanS sensor kinase has
been reported for glycopeptide-resistant enterococci and, re-
cently, for S. coelicolor (5, 7, 13, 22). We have taken advantage
of the high degree of identity (77%) between the VanS se-
quences of S. coelicolor (EMBL accession no. AL939117.1)
and A. teichomyceticus (EMBL accession no. AJ632270.1) to
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check for the presence and significance of possible mutations
in the VanS protein of A. teichomyceticus. By sequence align-
ment, we found two significant amino acid differences, located
at positions 215 and 270 (positions 216 and 271, respectively, in
S. coelicolor). Amino acids L216 and G271, located in the
ATPase domain of VanS, have been reported to be crucial for
the VanS phosphorylase activity in S. coelicolor, since their
mutation (L216P and G271V) resulted in constitutive van gene
expression and subsequent constitutive resistance (22). The
differences in these amino acids (L216 and G271 of S. coeli-
color have the orthologs N215 and R270, respectively, in A.
teichomyceticus) suggest that A. teichomyceticus also has an
impaired phosphatase function. In this actinomycete, a mu-
tated VanS homolog conferring constitutive glycopeptide re-
sistance may have been selected as an adaptation to teicopla-
nin production. Previous results on the marginal effect of
cloning of A. teichomyceticus van genes in S. coelicolor (47) to
teicoplanin resistance are likely due to complementation by
the fully functional VanS homolog of S. coelicolor, which main-
tains an inducible phenotype of vancomycin resistance and
teicoplanin sensitivity.
Resistance to vancomycin and teicoplanin in A. teichomyce-
ticus. Detailed studies of the resistance phenotypes of glyco-
peptide-producing microorganisms are not reported in the lit-
erature. The standard method used to determine MICs for
mycelial actinomycetes is hampered by the formation of mul-
ticellular aggregates and by the copresence of cells in different
differentiation phases (i.e., vegetative mycelium, aerial myce-
lium, and spores) (35). We obtained hyphal preparations that
could be converted to dispersed bacterial populations by use of
a properly balanced protocol of sonication/filtration that was
able to disrupt pellets and detach small hyphal fragments with-
out damaging cell integrity. Under these conditions, A. teicho-
myceticus was resistant to glycopeptides, showing MICs of
teicoplanin and vancomycin of 25 mg/ml and 90 mg/ml, respec-
tively. These levels of glycopeptide resistance resemble those
reported for intermediately resistant pathogenic enterococci,
such as VanD isolates (42). The growth of A. teichomyceticus in
the presence of teicoplanin or vancomycin at subinhibitory
concentrations before MIC determination did not cause any
changes in the MICs.
Determination of structures of peptidoglycan precursors. In
enterococci the expression of van genes redirects cell wall
biosynthesis toward the modified UDP–muropentapeptides
UDP-MurNAc–L-Ala–D-Glu–L-Lys–D-Ala–D-Lac or UDP-Mur-
NAc–L-Ala–D-Glu–L-Lys–D-Ala–D-Ser (42). To characterize
the cell wall precursors in A. teichomyceticus ATCC 31121, cell
wall assembly was blocked by the addition of ramoplanin, as
reported in the literature (2). This depsipeptide antibiotic is
structurally unrelated to vancomycin and teicoplanin, inhibits
peptidoglycan transglycosylases (21), and is devoid of any ef-
fect on the induction of van gene expression in Enterococcus
faecalis and S. coelicolor (6, 22). The cell wall precursor pool in
ramoplanin-treated cells was analyzed by liquid chromatogra-
phy (LC)-MS. A major peak was found to elute at a retention
time of 17.8 min (Fig. 1B). As untreated cells did not exhibit
this peak (Fig. 1A), it thus appeared to be related to a cell wall
precursor that accumulated as a result of the effect of ramo-
planin. The positive-ion ESI-MS spectrum corresponding to
this peak revealed the presence of two quasimolecular ions,
[M-H]1, at m/z 1196.9 and 1212.9 (data not shown). The neg-
ative-ion spectrum (Fig. 2A) showed quasimolecular ions,
[M-H]2, at m/z 1195.2 and 1211.0 and the double-charged ions,
[M-2H]22, at m/z 597.1 and 605.1, in agreement with the pres-
ence of two molecular species with the molecular formulas
C40H62N8O30P2 and C40H62N8O31P2 and corresponding to
calculated monoisotopic molecular masses of 1,196.30 and
1,212.30 Da, respectively. The UDP-N-glycolylmuramyl dep-
sipeptide structure UDP-N-glycolylmuramyl–Gly–D-Glu–meso-
diaminopimelic acid (mDap)–D-Ala–D-Lac was attributed to
the species showing a quasimolecular ion, [M-H]2, at m/z
1195.2 (Fig. 2C). This depsipeptide contains the D-Ala–D-Lac
terminus characteristic of the VanA, VanB, and VanD pheno-
types (42) and a remaining part consistent with data in the
literature (23). In fact, in Actinoplanes species and in some
other actinomycetes, the glycolyl group is present instead of
acetyl groups in muramic acid and the composition of the
peptide unit is glycine, glutamic acid, meso-diaminopimelic
acid (or meso-3-hydroxy-diaminopimelic acid), and alanine
(23). The difference of 16 mass units between the molecular
mass of the two species which coelute by LC-MS at 17.8 min
suggests the presence of a hydroxy group on the UDP-N-
glycomuramyl–Gly–D-Glu–mDap–D-Ala–D-Lac, probably on
the meso-diaminopimelic acid (indicated by R in Fig. 2C), as
also reported for Actinoplanes species and in other actinomy-
cetes (23). Additional evidence for the UDP-N-glycolylmu-
ramyl–Gly–D-Glu–mDap–D-Ala–D-Lac structure was provided
by MS-MS analysis in the negative-ion mode of the quasimo-
lecular ion [M-H]2 corresponding to the UDP-muropentadep-
FIG. 1. LC-MS analysis of the cell wall cytoplasmatic precursor
pool in ramoplanin-treated mycelium (B) or untreated mycelium
(A) of A. teichomyceticus. Bacterial cultures were grown, harvested,
and extracted as reported in Materials and Methods. Detection was by
ESI-MS. A major peak, detectable only in ramoplanin-treated cells at
a retention time of 17.8 min (indicated by the arrow), corresponded to
the cell wall precursor UDP-N-glycolylmuramyl–Gly–D-Glu–mDap–D-
Ala–D-Lac (as identified by ESI-MS). No trace of precursors termi-
nating in D-Ala–D-Ala was detected. The other peaks present on the
HPLC plot showed MS profiles not related to soluble peptidoglycan
precursors.
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sipeptide mentioned above (Fig. 2B). Significant fragments are
evidenced in Fig. 2C. Fragmentation of the molecular ion at
m/z 1195.2 gave a product ion at m/z 1123.1, corresponding to
the loss of 72 mass units equivalent to a lactate (Lac) fragment
and thus corresponding to the sequence UDP-N-glycolylmu-
ramyl–Gly–D-Glu–mDap–D-Ala. The fragmentation ions at
m/z 871.2 and 791.1 corresponded to the loss of UMP or UDP
from the UDP-muropentadepsipeptide, giving P–N-glycolyl-
muramyl–Gly–D-Glu–mDap–D-Ala–D-Lac and N-glycolylmu-
ramyl–Gly–D-Glu–mDap–D-Ala–D-Lac, respectively. The ion
at m/z 403.0 corresponded to UDP, while the ions at m/z 1105.2
and 1087.3 were attributed to losses of lactic acid and lactic
acid plus water, respectively, from the quasimolecular ion.
Among the ions with a relative abundance of less than 30%
(Fig. 2B), it was possible to assign those at m/z 951.2 and 799.3,
which were attributed to the loss of uridine and UMP plus
lactate, respectively.
The LC/MS profiles of ramoplanin-treated cells cultured
either in glycopeptide-free vegetative medium or in vegetative
medium to which vancomycin or teicoplanin was added were
virtually identical (data not shown). In all these preparations,
the only UDP-muropentapeptide recovered was the one ter-
minating with the depsipeptide D-Ala–D-Lac. No traces of D-
Ala–D-Ala UDP-N-glycolylmuramylpentapeptide (expected
[M-H]2 at m/z 1194) were detected (Fig. 2). This further con-
firms that the van genes are constitutively expressed in A.
teichomyceticus. We cannot rule out the possibility that pepti-
doglycan precursors terminating in D-Ala–D-Ala are also syn-
thesized, but in this case they should be very efficiently and
completely converted to the D-Ala–D-Lac-terminating ones.
These data, together with those on the constitutive transcrip-
tion of van genes in RT-PCR experiments and with the MICs
of either vancomycin or teicoplanin, define a constitutive phe-
notype of glycopeptide resistance in A. teichomyceticus with
features similar to those described in VanD enterococci. In
fact, VanD enterococci are intermediately resistant to vanco-
mycin and teicoplanin, their van genes are constitutively tran-
scribed, and the UDP-muropentapeptide terminates with D-
Ala–D-Lac independently from the presence of glycopeptides
in the cultivation medium (41).
Teicoplanin production and glycopeptide resistance. Resis-
tance could be coregulated with endogenous antibiotic produc-
tion in antibiotic-producing microorganisms, and an increase
of self-resistance during antibiotic production has been re-
ported previously (12). The proximity of the van genes to the
tcp cluster in A. teichomyceticus may imply some mechanism of
coregulation (47–49). Figure 3 shows the correlations among
growth, teicoplanin production, and MIC at different times of
A. teichomyceticus cultivation in the antibiotic production me-
dium. The teicoplanin MIC at the beginning of fermentation
was the same as that in vegetative cultures (25 mg/ml), and then
FIG. 2. (A) Full-scan mass spectrum (negative ion current) of the
peak eluted at 17.8 min. The molecular ion [M-H]2 at m/z 1195.2
corresponded to the UDP-N-glycolylmuramyl–Gly–D-Glu–mDap–D-
Ala-D-Lac and double-charged [M-H]22 at m/z 597.1. UDP-N-glyco-
lylmuramyl–Gly–D-Glu–m-3-hydroxy-Dap–D-Ala–D-Lac is identifiable
by the molecular ion [M-H]2 at 1211.0 and double-charged [M-2H]22
at m/z 605.0. The ion at m/z 402.9 corresponded to UDP formed
directly in the MS source. (B) MS-MS analysis of the quasimolecular
ion [M-H]2 at m/z 1195.2. (C) Chemical structure of the UDP-N-glyco-
lylmuramyl–Gly–D-Glu–mDap–D-Ala–D-Lac (R 5 H) or of the UDP-N-
glycolylmuramyl–Gly–D-Glu–m-3-hydroxy-Dap–D-Ala–D-Lac (R 5 OH)
and structural assignments for the main fragment ions. Note that the
masses of the observed fragment ions (numbers above arrows) are 1 Da
smaller than the masses of the neutral structures due to the loss of H1.
FIG. 3. Teicoplanin MICs (thick bars) in A. teichomyceticus myce-
lium prepared from fermentation flasks during teicoplanin production.
The levels of production of teicoplanin (reported as mg/liter }) and
growth (reported as g/liter [dry weight] of mycelium Œ) at the different
fermentation intervals are indicated. The results are the averages of
three independent experiments. Bars represent 6 1 standard devia-
tion.
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it showed a slight, transient increase (33 mg/ml) at the end of
the exponential phase of growth and finally decreased during
the stationary phase, in association with maximal antibiotic
production. At 48 h after inoculation (exponential phase of
growth), teicoplanin was produced at about 20 mg/ml and
reached 70 to 80 mg/ml at 96 h of fermentation (stationary
phase of growth).
Because glycopeptides are reported to exert bactericidal ac-
tions in pathogens (26), the minimal bactericidal concentra-
tions of teicoplanin and vancomycin were determined. In A.
teichomyceticus more than 20% of the population survived 24 h
of exposure to teicoplanin at 5,000 mg/ml, and treatment with
the same vancomycin concentration allowed 50% survival. The
control antibiotic kanamycin showed, instead, bactericidal ac-
tion at much lower concentrations (data not shown).
It can be concluded that teicoplanin as well as vancomycin is
not bactericidal for A. teichomyceticus. Thus, this microorgan-
ism fails to grow in the presence of more than 25 mg/ml of
teicoplanin but could resume growth if the antibiotic is re-
moved. The maximum level of teicoplanin production (80 mg/
ml) in submerged cultures is higher than the MIC, but teico-
planin production occurs in the late exponential-stationary
phase of growth, when scarce mycelium proliferation is re-
ported. Under these physiological conditions, the activity
of cell wall biosynthesis per se is reduced. The mechanisms of
van-mediated resistance appear to be involved in the phase of
active growth, when the levels of teicoplanin production are
usually at sub-MICs. As the strain enters into the stationary
phase, resistance is no longer required and the nonproliferat-
ing cells are tolerant to high concentrations of their own prod-
uct. When Pootoolal and coworkers (43) knocked out the
vanA-like gene conferring A47934 resistance to the producer
strain S. toyocaensis NRRL15009, the mutant retained the abil-
ity to produce the antibiotic, but its production was delayed for
more than 16 h. Probably, also in this case, antibiotic produc-
tion was delayed to a period when cells have ceased growing
and are predicted to become insensitive to antibiotic action.
Analysis of the temporal succession of growth and resis-
tance, antibiotic production, and tolerance in A. teichomyceti-
cus brings our attention back to the complex life cycle of this
nonmotile saprophytic filamentous soil actinomycete, which
grows by colonizing solid substrates with vegetative hyphal
mass and then differentiates into aerial structures with motile
spores that assist species spread and persistence. In nature,
antibiotic production starts when the growth of the vegetative
mycelium slows down as a result of nutrient exhaustion and
secondary structures evolve at the expense of the nutrients
released by the breakdown of vegetative cells at the center of
the colony. It has been proposed that antibiotics defend the
food source from the threat of competitors, without damaging
the cells that differentiate into spores, which should tolerate
high local concentrations. Meanwhile, the expression of anti-
biotic resistance genes may be an advantage to mycelium that
is still growing at the borders of the colony, where the antibi-
otic diffuses at low concentrations from the center. In conclu-
sion, resistance allows the growth and spread of vegetative
mycelium, while antibiotic production protects the center of
the colony, which has switched to the sporulating phase.
ACKNOWLEDGMENTS
Arianna Consolandi was supported by a grant from the Consorzio
Roberto Lepetit.
We are grateful to Giancarlo Lancini and Luigi Zerilli for kindly
revising this work. Teicoplanin was a gift from Aventis Bulk (Anagni,
Italy).
REFERENCES
1. Arthur, M., F. Depardieu, C. Molinas, P. Reynolds, and P. Courvalin. 1995.
The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers re-
sistance to teicoplanin. Gene 154:87–92.
2. Arthur, M., F. Depardieu, P. Reynolds, and P. Courvalin. 1996. Quantitative
analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors
of glycopeptide-resistant enterococci. Mol. Microbiol. 21:33–44.
3. Arthur, M., C. Molinas, and P. Courvalin. 1992. Sequence of the vanY gene
required for production of a vancomycin-inducible D,D-carboxypeptidase in
Enterococcus faecium BM4147. Gene 120:111–114.
4. Arthur, M., C. Molinas, F. Depardieu, and P. Courvalin. 1993. Character-
ization of Tn1546, a Tn3-related transposon conferring glycopeptide resis-
tance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus
faecium BM4147. J. Bacteriol. 175:117–127.
5. Arthur, M., and R. Quintiliani, Jr. 2001. Regulation of VanA- and VanB-
type glycopeptide resistance in enterococci. Antimicrob. Agents Chemother.
45:375–381.
6. Baptista, M., F. Depardieu, P. Courvalin, and M. Arthur. 1996. Specificity of
induction of glycopeptide resistance genes in Enterococcus faecalis. Antimi-
crob. Agents Chemother. 40:2291–2295.
7. Baptista, M., F. Depardieu, P. Reynolds, P. Courvalin, and M. Arthur. 1997.
Mutations leading to increased levels of resistance to glycopeptide antibiot-
ics in VanB-type enterococci. Mol. Microbiol. 25:93–105.
8. Bentley, S. D., K. F. Chater, A. M. Cerdeno-Tarraga, G. L. Challis, N. R.
Thomson, K. D. James, D. E. Harris, M. A. Quail, H. Kieser, D. Harper,
A. Bateman, S. Brown, G. Chandra, C. W. Chen, M. Collins, A. Cronin,
A. Fraser, A. Goble, J. Hidalgo, T. Hornsby, S. Howarth, C. H. Huang,
T. Kieser, L. Larke, L. Murphy, K. Oliver, S. O’Neil, E. Rabbinowitsch,
M. A. Rajandream, K. Rutherford, S. Rutter, K. Seeger, D. Saunders, S.
Sharp, R. Squares, S. Squares, K. Taylor, T. Warren, A. Wietzorrek, J.
Woodward, B. G. Barrell, J. Parkhill, and D. A. Hopwood. 2002. Com-
plete genome sequence of the model actinomycete Streptomyces coelicolor
A3(2). Nature 417:141–147.
9. Bugg, T. D., G. D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, and
C. T. Walsh. 1991. Molecular basis for vancomycin resistance in Enterococcus
faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by
vancomycin resistance proteins VanH and VanA. Biochemistry 30:10408–
10415.
10. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus
resistant to vancomycin—United States, 2002. Morb. Mortal. Wkly. Rep.
51:565–567.
11. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant
Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. Rep. 51:
902.
12. Cundliffe, E. 1992. Self-protection mechanisms in antibiotic producers. Ciba
Found. Symp. 171:191–208.
13. Depardieu, F., M. Kolbert, H. Pruul, J. Bell, and P. Courvalin. 2004. VanD-
type vancomycin-resistant Enterococcus faecium and Enterococcus faecalis.
Antimicrob. Agents Chemother. 48:3892–3904.
14. Donadio, S., M. Sosio, E. Stegmann, T. Weber, and W. Wohlleben. 2005.
Comparative analysis and insights into the evolution of gene clusters for
glycopeptide antibiotic biosynthesis. Mol. Genet. Genomics 9:40–50.
15. Evers, S., and P. Courvalin. 1996. Regulation of VanB-type vancomycin
resistance gene expression by the VanSB-VanRB two-component regulatory
system in Enterococcus faecalis V583. J. Bacteriol. 178:1302–1309.
16. Evers, S., D. F. Sahm, and P. Courvalin. 1993. The vanB gene of vancomy-
cin-resistant Enterococcus faecalis V583 is structurally related to genes en-
coding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and
VanC. Gene 124:143–144.
17. Garnier, F., S. Taourit, P. Glaser, P. Courvalin, and M. Galimand. 2000.
Characterization of transposon Tn1549, conferring VanB-type resistance in
Enterococcus spp. Microbiology 146:1481–1489.
18. Ge, M., Z. Chen, H. R. Onishi, J. Kohler, L. L. Silver, R. Kerns, S. Fukuzawa,
C. Thompson, and D. Kahne. 1999. Vancomycin derivatives that inhibit pepti-
doglycan biosynthesis without binding D-Ala–D-Ala. Science 284:507–511.
19. Guardabassi, L., H. Christensen, H. Hasman, and A. Dalsgaard. 2004.
Members of the genera Paenibacillus and Rhodococcus harbor genes homol-
ogous to enterococcal glycopeptide resistance genes vanA and vanB. Anti-
microb. Agents Chemother. 48:4915–4918.
20. Hong, H. J., M. I. Hutchings, J. M. Neu, G. D. Wright, M. S. Paget, and M. J.
Buttner. 2004. Characterization of an inducible vancomycin resistance sys-
tem in Streptomyces coelicolor reveals a novel gene (vanK) required for drug
resistance. Mol. Microbiol. 52:1107–1121.
1140 BELTRAMETTI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
o
v
e
m
b
e
r 1
0
, 2
0
1
6
 b
y
 U
n
iv
e
rs
ita
 D
e
ll In
s
u
b
ria
h
ttp
://a
a
c
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
21. Hu, Y., J. S. Helm, L. Chen, X. Y. Ye, and S. Walker. 2003. Ramoplanin
inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am.
Chem. Soc. 125:8736–8737.
22. Hutchings, M. I., H. J. Hong, and M. J. Buttner. 2006. The vancomycin
resistance VanRS two-component signal transduction system of Streptomyces
coelicolor. Mol. Microbiol. 59:923–935.
23. Kawamoto, I., T. Oka, and T. Nara. 1981. Cell wall composition of Mi-
cromonospora olivoasterospora, Micromonospora sagamiensis, and related or-
ganisms. J. Bacteriol. 146:527–534.
24. Kieser, T., M. J. Bibb, M. J. Buttner, K. F. Chater, and D. A. Hopwood. 2000.
Practical Streptomyces genetics. The John Innes Foundation, Norwich,
United Kingdom.
25. Kohlrausch, U., and J. V. Holtje. 1991. One-step purification procedure for
UDP-N-acetylmuramyl-peptide murein precursors from Bacillus cereus.
FEMS Microbiol. Lett. 62:253–257.
26. Lancini, G. C., and B. Cavalleri. 1990. Glycopeptide antibiotics of the van-
comycin group, p. 159–178. In H. Kleinkauf and H. von Dohren (ed.),
Biochemistry of peptide antibiotics. Walter de Gruyter, Berlin, Germany.
27. Lancini, G. C., and R. Lorenzetti. 1993. Biotechnology of the antibiotics and
other bioactive microbial metabolites. Plenum Press, New York, NY.
28. Lessard, I. A., S. D. Pratt, D. G. McCafferty, D. E. Bussiere, C. Hutchins,
B. L. Wanner, L. Katz, and C. T. Walsh. 1998. Homologs of the vancomycin
resistance D-Ala–D-Ala dipeptidase VanX in Streptomyces toyocaensis, Esch-
erichia coli and Synechocystis: attributes of catalytic efficiency, stereoselec-
tivity and regulation with implications for function. Chem. Biol. 5:489–504.
29. Li, T. L., F. Huang, S. F. Haydock, T. Mironenko, P. F. Leadlay, and J. B.
Spencer. 2004. Biosynthetic gene cluster of the glycopeptide antibiotic teico-
planin: characterization of two glycosyltransferases and the key acyltrans-
ferase. Chem. Biol. 11:107–119.
30. Marshall, C. G., I. A. Lessard, I. Park, and G. D. Wright. 1998. Glycopeptide
antibiotic resistance genes in glycopeptide-producing organisms. Antimi-
crob. Agents Chemother. 42:2215–2220.
31. Marshall, C. G., and G. D. Wright. 1998. DdlN from vancomycin-producing
Amycolatopsis orientalis C329.2 is a VanA homologue with D-alanyl–D-lactate
ligase activity. J. Bacteriol. 180:5792–5795.
32. Marshall, C. G., and G. D. Wright. 1997. The glycopeptide antibiotic pro-
ducer Streptomyces toyocaensis NRRL 15009 has both D-alanyl–D-alanine
and D-alanyl–D-lactate ligases. FEMS Microbiol. Lett. 157:295–299.
33. Marshall, C. G., M. Zolli, and G. D. Wright. 1999. Molecular mechanism of
VanHst, an alpha-ketoacid dehydrogenase required for glycopeptide antibi-
otic resistance from a glycopeptide producing organism. Biochemistry 38:
8485–8491.
34. Meziane-Cherif, D., M. A. Badet-Denisot, S. Evers, P. Courvalin, and B.
Badet. 1994. Purification and characterization of the VanB ligase associated
with type B vancomycin resistance in Enterococcus faecalis V583. FEBS Lett.
354:140–142.
35. Miyadoh, S. 1997. Atlas of actinomycetes. Asakura Publishing Co., Shin-
jukuku, Tokyo, Japan.
36. Murphy, L. D., C. E. Herzog, J. B. Rudick, A. T. Fojo, and S. E. Bates. 1990.
Use of the polymerase chain reaction in the quantitation of mdr-1 gene
expression. Biochemistry 29:10351–10356.
37. National Committee for Clinical Laboratory Standards. 1997. Methods for
dilution antimicrobial susceptibility tests for bacteria that grow aerobically.
M7-A4, vol. 17. National Committee for Clinical Laboratory Standards, Wayne,
Pa.
38. Nieto, M., and H. R. Perkins. 1971. Modifications of the acyl-D-alanyl–D-
alanine terminus affecting complex-formation with vancomycin. Biochem. J.
123:789–803.
39. Patel, R. 2000. Enterococcal-type glycopeptide resistance genes in non-en-
terococcal organisms. FEMS Microbiol. Lett. 185:1–7.
40. Patel, R., K. Piper, F. R. Cockerill III, J. M. Steckelberg, and A. A. Yousten.
2000. The biopesticide Paenibacillus popilliae has a vancomycin resistance
gene cluster homologous to the enterococcal VanA vancomycin resistance
gene cluster. Antimicrob. Agents Chemother. 44:705–709.
41. Perichon, B., P. Reynolds, and P. Courvalin. 1997. VanD-type glycopeptide-
resistant Enterococcus faecium BM4339. Antimicrob. Agents Chemother.
41:2016–2018.
42. Pootoolal, J., J. Neu, and G. D. Wright. 2002. Glycopeptide antibiotic resis-
tance. Annu. Rev. Pharmacol. Toxicol. 42:381–408.
43. Pootoolal, J., M. G. Thomas, C. G. Marshall, J. M. Neu, B. K. Hubbard, C. T.
Walsh, and G. D. Wright. 2002. Assembling the glycopeptide antibiotic scaffold:
the biosynthesis of A47934 from Streptomyces toyocaensis NRRL15009. Proc.
Natl. Acad. Sci. USA 99:8962–8967.
44. Reynolds, P. E. 1989. Structure, biochemistry and mechanism of action of
glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8:943–950.
45. Reynolds, P. E., F. Depardieu, S. Dutka-Malen, M. Arthur, and P. Courvalin.
1994. Glycopeptide resistance mediated by enterococcal transposon Tn1546
requires production of VanX for hydrolysis of D-alanyl–D-alanine. Mol. Micro-
biol. 13:1065–1070.
46. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, NY.
47. Serina, S., F. Radice, S. Maffioli, S. Donadio, and M. Sosio. 2004. Glyco-
peptide resistance determinants from the teicoplanin producer Actinoplanes
teichomyceticus. FEMS Microbiol. Lett. 240:69–74.
48. Sosio, M., A. Bianchi, E. Bossi, and S. Donadio. 2000. Teicoplanin biosyn-
thesis genes in Actinoplanes teichomyceticus. Antonie Leeuwenhoek 78:379–
384.
49. Sosio, M., H. Kloosterman, A. Bianchi, P. de Vreugd, L. Dijkhuizen, and S.
Donadio. 2004. Organization of the teicoplanin gene cluster in Actinoplanes
teichomyceticus. Microbiology 150:95–102.
50. Wright, G. D., C. Molinas, M. Arthur, P. Courvalin, and C. T. Walsh. 1992.
Characterization of VanY, a D,D-carboxypeptidase from vancomycin-resis-
tant Enterococcus faecium BM4147. Antimicrob. Agents Chemother. 36:
1514–1518.
51. Wu, Z., G. D. Wright, and C. T. Walsh. 1995. Overexpression, purification,
and characterization of VanX, a D,D-dipeptidase which is essential for van-
comycin resistance in Enterococcus faecium BM4147. Biochemistry 34:2455–
2463.
VOL. 51, 2007 A. TEICHOMYCETICUS van-MEDIATED GLYCOPEPTIDE RESISTANCE 1141
 o
n
 N
o
v
e
m
b
e
r 1
0
, 2
0
1
6
 b
y
 U
n
iv
e
rs
ita
 D
e
ll In
s
u
b
ria
h
ttp
://a
a
c
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
